Management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78(2):249-261.
10. Migden R, Rischin M, Schmults D, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. New Engl J Med. 2018;379:341-351.
11. Farberg AS, Wysong A, Newman JG, et al. Development of a multi-gene expression profile for recurrence risk prediction in cutaneous squamous cell carcinoma. Poster presented at: American Society for Dermatologic Surgery Annual Meeting; October 14, 2018; Pheonix, AZ.
12. Farberg AS, Glazer AM, White R, et al. Impact of a 31-gene expression profiling test for cutaneous melanoma on dermatologists' clinical management decisions. J Drugs Dermatol. 2017;16(5):428-431.
13. Ferris LK, Farberg AS, Middlebrook B, et al. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. J Am Acad Dermatol. 2017;76(5):818-825.e3.
10. Migden R, Rischin M, Schmults D, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. New Engl J Med. 2018;379:341-351.
11. Farberg AS, Wysong A, Newman JG, et al. Development of a multi-gene expression profile for recurrence risk prediction in cutaneous squamous cell carcinoma. Poster presented at: American Society for Dermatologic Surgery Annual Meeting; October 14, 2018; Pheonix, AZ.
12. Farberg AS, Glazer AM, White R, et al. Impact of a 31-gene expression profiling test for cutaneous melanoma on dermatologists' clinical management decisions. J Drugs Dermatol. 2017;16(5):428-431.
13. Ferris LK, Farberg AS, Middlebrook B, et al. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. J Am Acad Dermatol. 2017;76(5):818-825.e3.
AUTHOR CORRESPONDENCE
Giselle Prado MD drgiselleprado@gmail.com